SOURCE: Amarillo Biosciences, Inc.

November 29, 2006 06:00 ET

Amarillo Biosciences to Present at the Wall Street Reporter Magazine "Small-Cap Discovery Conference" on December 5, 2006 in New York

AMARILLO, TX -- (MARKET WIRE) -- November 29, 2006 -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Dr. Joseph Cummins, President & CEO, will present the Company to fund managers, analysts and investment bankers at the Wall Street Reporter Magazine "Small-Cap Discovery Conference" on December 5, 2006 at The Princeton Club in New York City. (The Princeton Club is located at 15 West 43rd Street (between 5th and 6th Avenues), New York, NY.)

The Amarillo Biosciences presentation is scheduled for 9:20 a.m. EST. The Company's shareholders and those interested in the Company are welcome to attend the conference. Dr. Cummins will discuss the partnership in China and Taiwan announced this week with CytoPharm. Dr. Cummins will also discuss ongoing Phase 2 clinical trials in oral warts in HIV+ patients and in Behcet's disease. The Company's plans for influenza studies will also be discussed.

Beginning at 8:30 am, live presentations by medical, resource, and technology companies from Australia, Canada and the U.S. can be accessed via the "Small-Cap Discovery Conference" webpage www.wallstreetreporter.com/sdc and clicking on the link to the live conference. Webcasts of the presentations will also be available following the live conference.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Behçet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. Additional information is available on the ABI web site at www.amarbio.com.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2005.

About Wall Street Reporter Magazine, Inc.

Wall Street Reporter Magazine (est. 1843) is a leading multi-media provider of CEO interviews, conferences, roundtables, and industry-focused articles to the global investment community.

For more information, visit www.wallstreetreporter.com.

Contact Information

  • Investor Relations:
    Philippe Niemetz
    PAN Consultants, Ltd.
    Tel: 800-477-7570
    Tel: 212-344-6464
    Fax: 212-618-1276
    e-mail: Email Contact

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301
    e-mail: Email Contact